Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delaloge S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC. Loriot MA, et al. Bull Cancer. 2019 Sep;106(9):759-775. doi: 10.1016/j.bulcan.2019.04.013. Epub 2019 Jun 25. Bull Cancer. 2019. PMID: 31253356 French.
Pharmacogenetics of capecitabine in advanced breast cancer patients.
Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, Francoual M, Renée N, Ferrero JM, Foa C, Namer M, Lacarelle B, Milano G. Largillier R, et al. Clin Cancer Res. 2006 Sep 15;12(18):5496-502. doi: 10.1158/1078-0432.CCR-06-0320. Clin Cancer Res. 2006. PMID: 17000685
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E. Schmitt A, et al. J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855828
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C, Jacob JH, Milano G. Etienne-Grimaldi MC, et al. Br J Clin Pharmacol. 2012 May;73(5):776-85. doi: 10.1111/j.1365-2125.2011.04141.x. Br J Clin Pharmacol. 2012. PMID: 22486600 Free PMC article. Clinical Trial.
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Loriot MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C. Boyer JC, et al. Bull Cancer. 2014 Jun;101(6):533-53. doi: 10.1684/bdc.2014.1933. Bull Cancer. 2014. PMID: 24977443 Review. French.
82 results